

Minutes of the

3rd Annual General Meeting

of the shareholders of

medmix Ltd

held on

Wednesday, 24 April 2024, 10.00 a.m.

at

Lorzensaal, Dorfplatz 3, 6330 Cham, Switzerland

The chairman of the Board of Directors of medmix Ltd (the "**Chairman**"), Rob ten Hoedt, formally opens the 3rd Annual General Meeting of medmix Ltd at 10.00 a.m. He welcomes the shareholders in German and explains that the meeting will be held in English to reach medmix' stakeholders worldwide. He then continues in English, introduces himself and notes the following:

The invitation to today's Annual General Meeting was published in the Swiss Official Gazette of Commerce on 28 March 2024. This means that the statutory notice period of 20 days has been complied with. The agenda and the proposals were also sent to the shareholders on 28 March 2024.

Pursuant to Art. 699a and Art. 734 of the Swiss Code of Obligations ("**CO**"), the annual report, the compensation report and the auditor's reports must be made available to the shareholders no later than 20 days before the Annual General Meeting. This is the case. The complete annual report, including the compensation report and the auditor's reports, has been available on medmix' website since 22 February 2024. Furthermore, the résumés of the members of the Board of Directors proposed for re-election are available on medmix' website. The resumé of Susanne Hundsbaek-Pedersen, the proposed new member of the Board of Directors, is included in the invitation to today's Annual General Meeting.

In advance of the Annual General Meeting, no requests for the inclusion of items on the agenda were received from shareholders, nor were there any counterproposals or questions regarding items on the agenda.

The meeting is therefore convened in accordance with the law and the articles of association of medmix Ltd and constitutes a quorum with regard to the published agenda items.

The Chairman welcomes and introduces the members of the Board of Directors attending the meeting. He explains that Greg Poux-Guillaume is not standing for re-election. In the name of the Board of Directors, the Chairman thanks Greg Poux-Guillaume for his invaluable and relentless contributions to medmix. He then welcomes and introduces the members of the Executive Committee and explains that Girts Cimermans stepped down as Chief Executive Officer with effect as of April 10. The Chairman notes that Girts Cimermans had an instrumental role in establishing medmix as a stand-alone listed company. In the name of the Board of Directors, the Chairman thanks Girts Cimermans for his unwavering dedication and commitment to medmix' customers and employees as well as for his leadership.

The Chairman states that the Board of Directors decided to appoint René Willi, a current member of the Board of Directors, as new Chief Executive Officer. The Chairman notes that René Willi will leverage his extensive experience in the healthcare industry to lead the company into the next stage of profitable growth. The Chairman introduces René Willi, before handing over to him.

Speech by René Willi, designated Chief Executive Officer (effective June 1, 2024)

René Willi opens in German by speaking on his connection to medmix. He continues in English and states the following:

"I would like to thank the Board of Directors for the trust they placed in me. You can count on my dedication to build the future of medmix. My diverse roles have given me the opportunity to deeply understand our business. I am excited to share these insights and drive our company's growth on this dynamic journey.

In the last years, as most companies, we had to navigate through stormy seas but we also know that stormy seas create the best sailors. We have great people with unique competences and great talent at medmix. Our aspiration is to create value for all our stakeholders, for our customers, for our employees, for our investors and for the communities where we operate. We want to further strengthen our competitiveness by customer proximity, best-in-class service level and innovation.

The creation of our new European production hub for the Industry segment in Valencia makes our supply chain more resilient, and we are poised providing highest service level and quality. This becomes even more important in a world facing increased supply chain disruption. We want to ensure that customers can continue relying on us. In the last

years, medmix has built a solid base for growth in the healthcare markets. With the new site in Atlanta, we are closer to the customers in North America, the largest global healthcare market. We want to excel in innovation, whether it is in the area of sustainability, improving the workflows for the end-users and satisfying unmet customer needs. You elected me as a member of the Board of Directors of medmix for the first time in 2022. I will also be standing for re-election today to remain fully involved in medmix in the coming weeks. Upon taking up the CEO role, I will step down from the Board of Directors and be fully focused on managing the development of our group.”

René Willi hands back to the Chairman, who thanks him.

The Chairman welcomes Simon Niklaus, representing KPMG AG, Zurich, as well as Christof Helbling, representing the independent proxy, Proxy Voting Services GmbH.

The Chairman hands over to Christof Helbling. Christof Helbling confirms that, in accordance with Art. 689c para. 5 CO, he has provided the Board of Directors with general information on the voting instructions received from shareholders, no earlier than three working days prior to the Annual General Meeting. This general information included a summary of the yes-votes, no-votes, and abstentions for all agenda items.

The Chairman states that, in accordance with Art. 14 of the articles of association, today's Annual General Meeting is chaired by Rob ten Hoedt as Chairman. Xavier Schops acts as secretary. The Chairman then welcomes the vote counters, Christoph Bischofberger (Credit Suisse (Switzerland) Ltd) and Daniel Schmidt-Badou (Commerzbank AG, Zurich branch office).

The Chairman states that the minutes of last year's Annual General Meeting of 28 April 2023 have been made available on medmix' website within the statutory period.

The Chairman explains the functioning of the electronic voting devices that the shareholders received. For the vote on the discharge under agenda item 3, the voting devices of those shareholders who are not legally allowed to take part in this vote have been blocked in the system. Tiwel Holding AG also voluntarily accepted this restriction. The Chairman asks the shareholders to participate in a test question to check the functioning of their device.

The Chairman then explains that the Annual General Meeting shall pass resolutions on each of today's agenda items by a majority of the votes represented, in accordance with art. 15 para. 1 of the articles of association.

The Chairman explains where shareholders can register, should they wish to speak.

The Chairman points out that the meeting will be recorded on video.

Speech by Jennifer Dean, Chief Financial Officer

Jennifer Dean introduces herself and announces that she will present the key highlights of the year 2023. She states the following:

“Drug Delivery market segment continued its strong organic growth path, while Surgery market segment accelerated year-on-year in the second half to reach another record. Beauty market segment ended the year strongly even as the pace of product launch activity eased compared to the first half of the year. Dental market segment destocking effects continued into the second half of the year, as we explained in October. As Dental end markets are continuing to grow, we expect our customers' order patterns to normalize during 2024. Industry market segment revenue slowed towards the year end as customers were faced with lower demand and higher interest rates.

All the while, we continued to invest in our future growth and profitability. Our new Industry market segment plant in Spain is now able to produce our full product range, and our focus is on increasing production efficiency. Our Healthcare growth investments in Atlanta are on track, and the new plant is due to begin operations towards the middle of this year. We successfully acquired and integrated Qiaoyi into our Beauty market segment, providing us greater access to Asia, and especially China, the second-largest cosmetics market in the world. Last but not least, we took a 25% stake in AARDEX, a software-as-a-service company that focuses on medication adherence control in

clinical trials. AARDEX is involved in phase one clinical trials, providing medmix the opportunity to engage with Drug Delivery customers much earlier in the product development process.

For 2024, we expect year-on-year organic revenue growth of between 4% and 6%, and an improvement of our adjusted EBITDA margin to at least 20%. The Dental and Industry market segments represent major swing factors in our shorter-term growth and profit recovery. There is still uncertainty around the timing of this recovery, with our current assumption being a trend change in the second half of the year.

Our longer-term ambitions are unchanged, based on solid market fundamentals. Given the various challenges medmix has faced during the last two years, we believe it is prudent to focus on commercial rebound and key operations projects, and to revisit our mid-term targets, when the rebound of the business is confirmed, at the end of 2024.

We have defined with the medmix management team five key priorities for 2024: 1) Continue on our path of innovation and sustainability; 2) deliver to Surgery customers from our new healthcare production site in Atlanta, USA; 3) phase out interim Industry manufacturing and ramp up production efficiency in Valencia, Spain; 4) further expand growth in China and Asia from our accretive Beauty acquisition of Qiaoyi; and 5) continue to pursue measures to streamline and improve cost effectiveness across our operations."

Jennifer Dean thanks shareholders for their attention and support and hands back to the Chairman.

The Chairman expresses his appreciation for what medmix has become as a stand-alone company, with strengths in different spaces, and touches upon the future opportunities, in particular in the space of general health and healthcare. The Chairman highlights that healthcare is one of the most exciting spaces for business and impact, with healthcare representing unique opportunities for innovation. The Chairman closes his remarks by stating that he is very optimistic regarding the future of medmix.

The Chairman announces that, at today's Annual General Meeting, 29,897,893 registered shares are represented, out of which 44,953 are represented by shareholders and 29,852,940 are represented by the independent proxy. This means that 72,5% of the registered share capital is represented today. Each registered share has a nominal value of CHF 0.01.

Agenda item 1: Annual report 2023

Agenda item 1.1: Business review, financial statements of medmix Ltd and consolidated financial statements 2023, reports of the auditor

The annual report, containing the business review, the financial statements and the consolidated financial statements, as well as the reports of the auditor are available on medmix' website.

The Chairman reiterates the key numbers from the income statement of the holding company, medmix Ltd, for the financial year 2023: The parent company's accounts show an income of CHF 42.2 million and expenses of CHF 8.6 million, resulting in a net profit of CHF 33.6 million.

The Chairman mentions that medmix Ltd's statutory financial statements have been prepared according to the accounting principles of the Swiss Code of Obligations.

The auditor's reports are included in the section "Financial Reporting" of the annual report on pages 170 et seqq. (for the consolidated financial statements) and on pages 187 et seqq. (for the financial statements of medmix Ltd). The page numbers refer to the annual report that can be downloaded in PDF format from the website. The Chairman thanks KPMG AG for their work.

The Chairman states that the representative of KPMG AG, who is present, indicated, prior to the Annual General Meeting, that he has no additional comment to make on the reports.

The Chairman opens the discussion on this agenda item.

Hermann Walther, Burgdorf: The speaker asks the Chairman to elaborate on (i) the departure of Girts Cimermans and (ii) the risks of patent infringements and the monetary risks resulting therefrom.

With regard to the speaker's first question, the Chairman notes that there was an orderly transition process. The Chairman highlights Girts Cimerman's contributions to medmix. With regard to the speaker's second question, the Chairman agrees that, while medmix has a strong focus on patents and intellectual property in general, there are, as for any company in the healthcare space, risks related to unintentional patent infringement. However, the Chairman assures that medmix is very experienced in product development and in navigating the patent landscape.

As there are no further questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Board of Directors proposes that the business review, the financial statements of medmix Ltd and the consolidated financial statements 2023 be approved.

The Chairman announces that the Annual General Meeting approved the business review, the financial statements of medmix Ltd and the consolidated financial statements 2023 with the following results:

Majority	14,948,947
Votes in favor	29,769,360
Votes against	84,530
Abstentions	44,003

The Chairman states that medmix demonstrated a solid performance in 2023 despite challenging conditions. This would not have been possible without the dedication of medmix' employees. On behalf of the Board of Directors and the Executive Committee, the Chairman thanks all the employees for their commitment and performance.

Agenda item 1.2: Advisory vote on the compensation report 2023

The Chairman explains that agenda item 1.2 is a non-binding advisory vote.

The compensation report sets out the basic principles of medmix' compensation policy and plans, as well as the compensation of the members of the Board of Directors and the Executive Committee. The Chairman further explains the compensation policy of medmix for the Board of Directors and the Executive Committee.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Board of Directors proposes that the compensation report 2023, as included in the annual report 2023, be approved in a non-binding advisory vote.

The Chairman announces that the Annual General Meeting approved the compensation report 2023 in a non-binding advisory vote with the following results:

Majority	14,948,947
Votes in favor	23,669,772
Votes against	6,158,800
Abstentions	69,321

Agenda item 1.3: Advisory vote on the sustainability review 2023

The Chairman explains that agenda item 1.3 is a non-binding advisory vote.

The sustainability review sets out in detail the non-financial governance and strategy-specific elements that supplement the information presented in other sections of the annual report 2023, describing medmix' people and culture focus, and addressing the approach and progress against priorities and commitments on environmental matters, in particular CO₂ goals, social issues, employee-related issues, respect for human rights and medmix' efforts in combating corruption. The Chairman further refers to medmix' non-financial achievements and highlights.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Board of Directors proposes that the report on non-financial matters 2023 as included in the annual report 2023 be approved in a non-binding advisory vote.

The Chairman announces that the Annual General Meeting approved the sustainability review 2023 in a non-binding advisory vote with the following results:

Majority	14,948,947
Votes in favor	29,072,734
Votes against	757,996
Abstentions	67,163

Agenda item 2: Appropriation of annual result

The Board of Directors proposes to allocate the total balance of CHF 36,413,027, comprising the net profit for 2023 of CHF 33,551,684 and the retained profits of CHF 2,861,343, as follows: CHF 20,390,924 as ordinary dividend and CHF 16,022,104 as balance to be carried forward.

The Chairman explains that medmix pursues a dividend policy that takes into account the company's liquidity as well as its economic situation.

The proposal of the Board of Directors includes a gross dividend, before deduction of 35% Swiss withholding tax, of CHF 0.50 per share, payable on 30 April 2024. All shares held by medmix Ltd and its subsidiaries as treasury shares on the record date are not entitled to dividends.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Chairman notes that the Annual General Meeting has approved the appropriation of the annual result proposed by the Board of Directors with the following results:

Majority	14,948,947
Votes in favor	29,200,571
Votes against	663,513
Abstentions	33,809

Agenda item 3: Discharge

The Board of Directors proposes that discharge be granted to the members of the Board of Directors and the Executive Committee for the financial year 2023.

The Chairman reminds the shareholders that, according to Art. 695 CO, the persons who were involved in the management of the company do not have the right to vote on the present agenda item. Furthermore, the Chairman states that Tiwel Holding AG voluntarily also accepted the same restriction for all shares held by it.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote on the discharge of the members of the Board of Directors and the Executive Committee.

The Chairman notes that the Annual General Meeting has granted discharge to the members of the Board of Directors and the Executive Committee with the following results:

Majority	6,582,265
Votes in favor	13,041,077
Votes against	47,065
Abstentions	76,386

The Chairman thanks the shareholders for the trust they have placed in the Board of Directors and the Executive Committee.

Agenda item 4: Compensation of the Board of Directors and the Executive Committee

The Chairman comes to the vote on the compensation of the Board of Directors and the Executive Committee. He mentions that agenda item 4 is divided into two sub-items with two separate votes: part 1, "Compensation of the Board of Directors", and part 2, "Compensation of the Executive Committee".

For detailed explanations on the approval of the submitted compensation, the Chairman refers to the separate report of the Board of Directors that the shareholders received with the invitation to this Annual General Meeting.

On the compensation of the Board of Directors, the Chairman states that the maximum total amount submitted for approval relates to the compensation for the term from today's Annual General Meeting to the Annual General Meeting 2025.

The proposed maximum total amount of CHF 1,500,000, unchanged from last year, is based on the compensation for seven members of the Board of Directors of medmix Ltd. The members of the Board of Directors only receive a fixed compensation to ensure their independence. They do not receive any variable or performance-related compensation nor are they entitled to participate in medmix' pension plans. The compensation of the Board of Directors is partly paid in cash and partly in restricted stock units.

On the compensation of the Executive Committee, the Chairman states that the proposed maximum total amount relates to the compensation for the financial year 2025. He mentions that the Executive Committee has been enlarged by one member to better reflect the growth ambitions of medmix and further focus on good governance. The proposed amount of CHF 8,500,000, unchanged compared to last year, covers the maximum total compensation of the members of the Executive Committee, including social security charges. The total compensation consists of a fixed base salary and a variable component. The variable component comprises a short-term performance-related bonus (in cash) and a long-term performance-related performance share unit plan. This system is designed to motivate above-average performance and to recognize this performance accordingly.

The Chairman mentions that this is a maximum amount. In accordance with legal requirements, the calculation of the maximum total amount of compensation for the Executive Committee takes into account the potential maximum amounts under the variable component of compensation, *i.e.*, both the short-term and long-term incentive systems.

The compensation actually paid out will be disclosed in the compensation report for the financial year 2025 which will be submitted to the shareholders for an advisory vote.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the votes.

Agenda item 4.1: Compensation of the Board of Directors

The Annual General Meeting votes on the approval of the total amount for the compensation of the Board of Directors for the term from the Annual General Meeting 2024 until the end of the Annual General Meeting 2025 in the maximum amount of CHF 1,500,000.

The Chairman notes that the Annual General Meeting approved the maximum total compensation of the Board of Directors for the term from the Annual General Meeting 2024 until the end of the Annual General Meeting 2025 with the following results:

Majority	14,948,947
Votes in favor	29,066,803
Votes against	778,187
Abstentions	52,903

Agenda item 4.2: Compensation of the Executive Committee

The Chairman continues with the vote on agenda item 4.2.

The Annual General Meeting votes on the approval of the total amount for the compensation of the Executive Committee for the financial year 2025 in the maximum amount of CHF 8,500,000.

The Chairman notes that the Annual General Meeting has approved the maximum total compensation of the Executive Committee for the financial year 2025 with the following results:

Majority	14,948,947
Votes in favor	28,772,753
Votes against	1,070,637
Abstentions	54,503

Agenda item 5: Election of the Board of Directors

The Chairman mentions that agenda item 5 is divided into three sub-items with separate votes, namely agenda item 5.1 "Re-election of the Chairman of the Board of Directors", agenda item 5.2 "Re-election of the other members of the Board of Directors" and agenda item 5.3 "Election of Ms. Hundsbaek-Pedersen as a new member of the Board of Directors".

Agenda item 5.1: Re-election of the Chairman of the Board of Directors

Marco Musetti takes over and states that the Board of Directors proposes that the shareholders re-elect Rob ten Hoedt as member and Chairman of the Board of Directors for a term until the end of the Annual General Meeting 2025.

Marco Musetti explains that Rob ten Hoedt has been elected as a member of the Board of Directors and as a member of the Nomination and Remuneration Committee at the Annual General Meeting 2022, while he was elected as Chairman of the Board of Directors at the Annual General Meeting 2023. Rob ten Hoedt is Executive Vice President & President, Europe, Middle East & Africa (EMEA) and Asia-Pacific (APAC) of Medtronic. For a detailed biography of Rob ten Hoedt, Marco Musetti refers shareholders to medmix' website.

Marco Musetti opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, Marco Musetti proceeds to the election.

Marco Musetti announces that the Annual General Meeting has re-elected Rob ten Hoedt as member and Chairman of the Board of Directors with the following results:

Majority	14,948,947
Votes in favor	24,123,633
Votes against	5,738,756
Abstentions	35,504

Marco Musetti congratulates the Chairman on his re-election and hands back to him.

Agenda item 5.2: Re-election of the other members of the Board of Directors

The Chairman states that Greg Poux-Guillaume does not stand for re-election, and then introduces the members of the Board of Directors standing for re-election:

Marco Musetti has been elected as a member of the Board of Directors at the Annual General Meeting 2021. He has been vice-chairman of the Board of Directors since the Annual General Meeting 2021 and chairman of the Audit Committee since the Annual General Meeting 2022. He has been a member of the Board of Directors at several international companies, and was also a member of the Board of Directors of Sulzer Ltd from 2011 to April 2021.

Barbara Angehrn has been elected as a member of the Board of Directors at the Annual General Meeting 2022. She is also a member of the Nomination and Remuneration Committee since the Annual General Meeting 2022. Barbara Angehrn is Chief Executive Officer of Asceneuron since October 2023.

René Willi has been elected as a member of the Board of Directors at the Annual General Meeting 2022. Since then, he has also been a member of the Audit Committee. Since 2021, René Willi has been Chief Executive Officer of the Global Oral Reconstruction Group at Henry Schein Inc.

Daniel Flammer has been elected as a member of the Board of Directors at the Annual General Meeting 2022. He has also been a member of the Audit Committee since then. Daniel Flammer is Managing Partner of AR Financial Advisory AG in Zurich since April 2018.

David Metzger has been elected as a member of the Board of Directors at the Annual General Meeting 2022. At the Annual General Meeting 2023 he has also been elected as a member of the Nomination and Remuneration Committee. David Metzger is currently working for Liwet Holding AG.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the re-elections.

The Chairman starts with the re-election of Marco Musetti under agenda item 5.2.1. The Board of Directors proposes to re-elect Marco Musetti as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Marco Musetti to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	14,948,947
Votes in favor	28,479,164
Votes against	1,383,794
Abstentions	34,935

The Chairman continues with the re-election of Barbara Angehrn under agenda item 5.2.2. The Board of Directors proposes to re-elect Barbara Angehrn as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Barbara Angehrn to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	14,948,947
Votes in favor	29,805,386
Votes against	61,354
Abstentions	31,153

The Chairman continues with the re-election of René Willi under agenda item 5.2.3. The Board of Directors proposes to re-elect René Willi as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected René Willi to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	14,948,947
Votes in favor	29,180,851
Votes against	680,127
Abstentions	36,915

The Chairman continues with the re-election of Daniel Flammer under agenda item 5.2.4. The Board of Directors proposes to re-elect Daniel Flammer as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Daniel Flammer to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	14,948,947
Votes in favor	26,368,938
Votes against	3,491,011
Abstentions	37,944

The Chairman continues with the re-election of David Metzger under agenda item 5.2.5. The Board of Directors proposes to re-elect David Metzger as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected David Metzger to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	14,948,947
Votes in favor	27,518,406
Votes against	2,339,731
Abstentions	39,756

Agenda item 5.3: Election of Ms. Susanne Hundsbaek-Pedersen as new member of the Board of Directors

The Chairman states that the Board of Directors proposes to elect Susanne Hundsbaek-Pedersen as a new member of the Board. As she is unable to attend the Annual General Meeting, the Chairman introduces her:

"Susanne Hundsbaek-Pedersen is a Danish national who serves since January 2021 as Executive Vice President, Global Head Pharma Technical Operations at F. Hoffmann-La Roche in Basel. In this role, she is responsible for all Technical Development, Manufacturing, Supply Chain, Quality and Regulatory activities within the Pharma division of Roche. Before joining Roche, she worked for about 18 years for Novo Nordisk in Denmark in numerous roles from Senior Project Manager, Director of Strategic Sourcing, to Senior Vice President for Supply for the Diabetes Products.

Susanne Hundsbaek-Pedersen graduated with a Diploma in Industrial Engineering from the Technical University of Copenhagen and an Executive MBA from the IMD Business School in Lausanne."

The Chairman states that, given the impressive professional experience of Susanne Hundsbaek-Pedersen, the Board of Directors is convinced that she would be a valuable new Board member and medmix could benefit from her long pharma industry experience.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the election.

The Chairman announces that the Annual General Meeting has elected Susanne Hundsbaek-Pedersen to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	14,948,947
Votes in favor	29,783,941
Votes against	85,036
Abstentions	28,916

The Chairman congratulates Susanne Hundsbaek-Pedersen on her election and welcomes her to the Board of Directors.

The Chairman mentions that the Board of Directors will reconstitute itself following the Annual General Meeting, and that the relevant decisions will be published. This concerns the election of the vice-chairperson of the Board of Directors, the election of the chairperson of the Nomination & Remuneration Committee, as well as the election and constitution of the Audit Committee, *i.e.*, the election of its members and chairperson.

Agenda item 6: Re-election of the Nomination & Remuneration Committee

The Chairman states that the Board of Directors proposes that shareholders re-elect Barbara Angehrn, Rob ten Hoedt, and David Metzger as members of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting. Barbara Angehrn and Rob ten Hoedt joined the Nomination & Remuneration Committee in 2022, while David Metzger was elected as a new member at last year's Annual General Meeting.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the re-elections.

The Board of Directors proposes to re-elect Barbara Angehrn as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Barbara Angehrn as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting with the following results:

Majority	14,948,947
Votes in favor	29,662,413
Votes against	200,902
Abstentions	34,578

The Chairman hands over to Marco Musetti who continues with the re-election of Rob ten Hoedt under agenda item 6.2. The Board of Directors proposes to re-elect Rob ten Hoedt as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting.

Marco Musetti notes that the Annual General Meeting has re-elected Rob ten Hoedt as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting with the following results:

Majority	14,948,947
Votes in favor	23,553,580
Votes against	6,305,268
Abstentions	39,045

Marco Musetti hands back over to the Chairman who continues with the re-election of David Metzger under agenda item 6.3. The Board of Directors proposes to re-elect David Metzger as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected David Metzger as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting with the following results:

Majority	14,948,947
Votes in favor	26,637,131
Votes against	3,220,267
Abstentions	40,495

Agenda item 7: Re-election of the Auditor

The Chairman continues with the re-election of the auditor.

The Board of Directors proposes to re-elect KPMG AG, Zurich, as auditor for the financial year 2024.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the election.

The Chairman notes that the Annual General Meeting has re-elected KPMG AG as auditor with the following results:

Majority	14,948,947
Votes in favor	29,792,270
Votes against	75,760
Abstentions	29,863

Agenda item 8: Re-election of the Independent Proxy

The Chairman continues with the re-election of the independent proxy under agenda item 8.

The Board of Directors proposes to re-elect Proxy Voting Services GmbH, Zurich, for a term until the end of the next Annual General Meeting as the independent proxy. Proxy Voting Services GmbH fulfils the requirements of independence, in particular because it is not connected to medmix through any other activities.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the election.

The Chairman notes that the Annual General Meeting has re-elected Proxy Voting Services GmbH, Zurich, for a term until the end of the next Annual General Meeting as independent proxy with the following results:

Majority	14,948,892
Votes in favor	29,860,220
Votes against	10,073
Abstentions	27,490

The Chairman closes this year's Annual General Meeting. He thanks shareholders for their interest and continued trust in medmix. He invites shareholders to a reception.

Closing of the meeting: 11:22 a.m.

The Chairman:



Rob ten Hoedt

The Secretary:



Xavier Schops